quinuclidines has been researched along with Leukemia, Myeloid, Acute in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 6 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cluzeau, T; Fenaux, P; Komrokji, R; Loschi, M; Sallman, DA | 1 |
| Sallman, DA | 1 |
| Daver, N; DiNardo, CD; Fathi, AT; Pollyea, DA; Vyas, P; Wei, AH | 1 |
| Birsen, R; Bouscary, D; Cantero-Aguilar, L; Chapuis, N; Decroocq, J; Fontenay, M; Gotanegre, M; Grignano, E; Guiraud, N; Huynh, T; Johnson, N; Kosmider, O; Larrue, C; Mayeux, P; Sarry, JE; Tamburini, J | 1 |
| Ades, L; Attalah, H; Berthon, C; Bève, B; Carpentier, AF; Chermat, F; Chevret, S; Cluzeau, T; Cuzzubbo, S; Fenaux, P; Komrokji, R; Lehmann-Che, J; Loschi, M; Madelaine, I; Miekoutima, E; Peterlin, P; Quesnel, B; Raffoux, E; Rahmé, R; Rauzy, OB; Recher, C; Sallman, DA; Sebert, M; Stamatoullas, A; Walter-Petrich, A; Willems, L | 1 |
| Cassinat, B; Diawara, Y; Fenaux, P; Giraudier, S; Maslah, N; Sebert, M | 1 |
| Ali, D; Jonson-Videsäter, K; Lehmann, S; Mohammad, DK; Mujahed, H; Nore, B; Paul, C | 1 |
| Bekele, BN; Blamble, DA; Borthakur, G; Cabanillas, M; Cortes, JE; Kantarjian, H; Mattiuzzi, GN; O'Brien, S; Xiao, L | 1 |
2 review(s) available for quinuclidines and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Humans; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Precision Medicine; Quinuclidines; Sulfonamides; Treatment Outcome; Tumor Suppressor Protein p53 | 2021 |
New directions for emerging therapies in acute myeloid leukemia: the next chapter.
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Quinuclidines; Sulfonamides | 2020 |
2 trial(s) available for quinuclidines and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Eprenetapopt Plus Azacitidine in
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Myelodysplastic Syndromes; Quinuclidines; Tumor Suppressor Protein p53 | 2021 |
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Isoquinolines; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Ondansetron; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2010 |
4 other study(ies) available for quinuclidines and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
To target the untargetable: elucidation of synergy of APR-246 and azacitidine in
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quinuclidines; Tumor Suppressor Protein p53 | 2020 |
APR-246 induces early cell death by ferroptosis in acute myeloid leukemia.
Topics: Cell Death; Ferroptosis; Humans; Leukemia, Myeloid, Acute; Quinuclidines | 2022 |
In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quinuclidines; Treatment Outcome; Tumor Cells, Cultured | 2021 |
Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells.
Topics: Gene Expression Regulation, Leukemic; Heme Oxygenase-1; Humans; Leukemia, Myeloid, Acute; NF-E2-Related Factor 2; Oxidative Stress; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinuclidines; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2016 |